QualityStocksNewsBreaks – CytoDyn Inc. (CYDY) Submits IND Application, Protocol for Phase 1b/2 Clinical Trial with PRO 140
CytoDyn (OTCQB: CYDY) this morning announced its submission of an investigational new drug (“IND”) application to the U.S. Food and Drug Administration (“FDA”) to carry out a phase 1b/2 clinical trial with PRO 140 as a therapy for metastatic triple-negative breast cancer. Currently, limited therapeutic options are available for triple-negative breast cancer due to an absence of standard biomarkers for targeted options. The original research and issued patents on CCR5 as a therapeutic target for cancer treatment were led by Richard Pestell, M.D., Ph.D., CytoDyn’s Interim Chief Medical Officer. Dr. Pestell’s published conclusions verified that CCR5 is a crucial receptor…